Atyr Pharma Inc (NASDAQ:ATYR)’s traded shares stood at 1.23 million during the last session, with the company’s beta value hitting 1.19. At the close of trading, the stock’s price was $3.25, to imply an increase of 0.31% or $0.01 in intraday trading. The ATYR share’s 52-week high remains $3.54, putting it -8.92% down since that peak but still an impressive 66.77% since price per share fell to its 52-week low of $1.08. The company has a valuation of $246.35M, with an average of 2.02 million shares in intraday trading volume over the past 10 days and average of 684.15K shares over the past 3 months.
Atyr Pharma Inc (NASDAQ:ATYR) trade information
After registering a 0.31% upside in the last session, Atyr Pharma Inc (ATYR) has traded red over the past five days. The 5-day price performance for the stock is 8.70%, and 86.78% over 30 days. With these gigs, the year-to-date price performance is 130.50%. Short interest in Atyr Pharma Inc (NASDAQ:ATYR) saw shorts transact 1.36 million shares and set a 4.1 days time to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Atyr Pharma Inc (ATYR) estimates and forecasts
Looking at statistics comparing Atyr Pharma Inc share performance against respective industry, we note that the company has underperformed competitors. Atyr Pharma Inc (ATYR) shares are 107.01% up over the last 6 months, with its year-to-date growth rate lower than industry average at 3.19% against 17.50%. Revenue is forecast to shrink -10.00% this quarter before jumping 8.00% for the next one. The rating firms project that company’s revenue will shrink -29.20% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 20k. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 20k.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 43.36% for the past 5-year period. While 2024 is set for a 5.62% return in earnings, projections for the next 5 years are at 13.00% annually.
ATYR Dividends
Atyr Pharma Inc has its next earnings report out on 2024-Nov-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
We also have Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund as the top two Mutual Funds with the largest holdings of the Atyr Pharma Inc (ATYR) shares. Going by data provided on Jul 31, 2024 , Federated Hermes Kaufmann Fund holds roughly 7.85 shares. This is just over 10.36% of the total shares, with a market valuation of $25.51 million. Data from the same date shows that the other fund manager holds a little less at 6.62, or 8.73% of the shares, all valued at about 21.52 million.
